Community Research and Development Information Service - CORDIS

Meeting the production challenges of biotechnology

As biotechnology pushes the boundaries of pharmaceutical endeavour, new ways of therapeutic intervention are fast gaining ground. Antibodies, although identified as immune system components for decades, present new research and treatment opportunities and also challenges in terms of their large scale production and isolation.
Meeting the production challenges of biotechnology
Production of macromolecules (including antibodies) using cells in an experimental setting, requires the specific selection of the cells of interest. It is an arduous process but a necessary one, given the need for increased purity for the final product.

A German technology, however, offers a novel alternative, which appears to simplify the screening and isolation procedure and is particularly adept for antibody-producing cells. The technology is based on the antibody's binding properties. The procedure involves the use of a specific toxin, the deleterious effects of which can only be inhibited if it binds to the target antibodies. Therefore, all non-antibody-producing cells are exposed to the toxic effects and eventually die.

The need for efficient, simple methods to isolate genetically engineered antibodies is on the increase, given the vast potential of these agents as therapeutics for a number of pathologies. Given the high costs associated with antibody production used for testing and research purposes, it becomes imperative to minimise costs and this current technology offers significant cost savings.

The inventors are looking for collaborative license agreements with suitable partners, who are in a position to further this research and optimise the technology. Patents have already been applied for and are pending.
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top